Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2022 | $28.00 → $30.00 | Buy | HC Wainwright & Co. |
| 11/15/2021 | $27.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $30.00 → $27.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously
For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc
LONDON, UK / ABU DHABI, UAE, July 20, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Syed Muhammad Nouman, FCA, as Group Finance Director, effective from July 20, 2026. Mr. Nouman will serve as the Company’s Principal Financial Officer and Principal Accounting Officer for SEC reporting purposes, as ratified by the Company’s Audit Committee. Mr. Nouman began his career at PwC, where he developed a strong foundation in audit and financial reporting. He is a Fellow Chartered Accountant (FCA) with mor
LONDON, UK / OSLO, NORWAY, July 13, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, is pleased to announce that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company with an Outperform rating and a $10.00 price target. The research report, authored by Noble Capital Markets Senior Research Analyst Michael Kupinski, is available on Channelchek, along with the latest news, market data, and additional information on Tectonic. Management encourages investors to review the report and visit Channelc
BESS integration targeted to unlock additional FCR-N, FCR-D and FFR Grid Reserve revenue streams Design would preserve the site's full leasable capacity for AI compute tenants Final investment decision subject to board approval, post completion of external feasibility study LONDON, UK / OSLO, NORWAY, July 06, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that it is progressing a formal technical and commercial feasibility study for the integration of a battery energy storage system ("BESS") at its 41.5 MW Mo i
3 - VivoPower PLC (0001681348) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
6-K - VivoPower PLC (0001681348) (Filer)
6-K - VivoPower PLC (0001681348) (Filer)
6-K/A - VivoPower PLC (0001681348) (Filer)
LONDON, UK / ABU DHABI, UAE, July 20, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Syed Muhammad Nouman, FCA, as Group Finance Director, effective from July 20, 2026. Mr. Nouman will serve as the Company’s Principal Financial Officer and Principal Accounting Officer for SEC reporting purposes, as ratified by the Company’s Audit Committee. Mr. Nouman began his career at PwC, where he developed a strong foundation in audit and financial reporting. He is a Fellow Chartered Accountant (FCA) with mor
LONDON, UNITED KINGDOM, July 02, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today provides the following update in respect of its strategic direction and the previously announced separation initiatives relating to its subsidiaries Tembo e-LV B.V. ("Tembo") and Caret Digital ("Caret Digital"). Following a strategic review, the Board of Directors of the Company has determined that VivoPower will focus, as a group and as its principal strategic priority, on the development and scale-up growth of its AI data center business and that
VivoPower's recertification extends its continuous B Corp status to 2028, eight years after its initial certification in April 2018 The recertification provides verified third-party assurance of VivoPower's governance, environmental, and stakeholder accountability standards as the Company scales its sovereign AI data center platform across the Nordics, Western Europe, and the Middle East Tembo Group has qualified under B Lab's brand review process to use the B Corp logo on its website, in addition to VivoPower's own continued use of the logo LONDON, June 16, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a
CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. This acquisition will help